0001144204-15-034844.txt : 20150601 0001144204-15-034844.hdr.sgml : 20150601 20150601162636 ACCESSION NUMBER: 0001144204-15-034844 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20150528 FILED AS OF DATE: 20150601 DATE AS OF CHANGE: 20150601 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CorMedix Inc. CENTRAL INDEX KEY: 0001410098 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1430 HIGHWAY 206 STREET 2: SUITE 200 CITY: BEDMINSTER STATE: NJ ZIP: 07921 BUSINESS PHONE: 908-517-9500 MAIL ADDRESS: STREET 1: 1430 HIGHWAY 206 STREET 2: SUITE 200 CITY: BEDMINSTER STATE: NJ ZIP: 07921 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lefkowitz Steven W CENTRAL INDEX KEY: 0001313149 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-34673 FILM NUMBER: 15903712 MAIL ADDRESS: STREET 1: SIX HARRISON STREET CITY: NEW YORK STATE: NY ZIP: 10013 4 1 form474701_20150601042516-.xml X0306 4 2015-05-28 0 0001410098 CorMedix Inc. CRMD 0001313149 Lefkowitz Steven W C/O CORMEDIX INC. 745 ROUTE 202-206, SUITE 303 BRIDGEWATER NJ US 08807 1 0 0 0 Common Stock, $0.001 par value per share 2015-05-28 4 S 0 10000 6.1602 D 146471 D Common Stock, $0.001 par value per share 2015-06-01 4 S 0 29072 6.6558 D 117399 D Common Stock, $0.001 par value per share 174741 I Wade Capital Corporation Money Purchase Plan Common Stock, $0.001 par value per share 10000 I Reporting Person's Wife Stock Option (right to buy) 2.02 2024-01-09 Common Stock, $0.001 par value per share 200000 200000 D Stock Option (right to buy) 2.02 2024-01-09 Common Stock, $0.001 par value per share 30000 30000 D Swries C-3 Non-Voting Convertible Preferred Stock 1 Common Stock, $0.001 par value per share 45000 4500 D Warrant (right to purchase Common Stock) 0.9 2015-01-08 2020-01-08 Common Stock, $0.001 par value per share 22500 22500 D Series C-3 Non-Voting Convertible Preferred Stock 1 Common Stock, $0.001 par value per share 30000 3000 I Wade Capital Corporation Money Purchase Plan Warrant (right to purchase Common Stock) 0.9 2015-01-08 2020-01-08 Common Stock, $0.001 par value per share 15000 15000 I Wade Capital Corporation Money Purchase Plan Warrant (right to purchase Common Stock) 3.4375 2012-08-20 2015-04-30 Common Stock, $0.001 par value per share 5000 0 D Stock Option (right to buy) 0.9 2023-03-20 Common Stock, $0.001 par value per share 120000 120000 D Stock Option (right to buy) 0.68 2022-12-05 Common Stock, $0.001 par value per share 150000 150000 D Stock Option (right to buy) 0.29 2022-01-06 Common Stock, $0.001 par value per share 30000 30000 D Stock Option (right to buy) 1.1 2021-08-11 Common Stock, $0.001 par value per share 30000 30000 D Warrant (right to purchase Common Stock) 3.4375 2015-04-30 Common Stock, $0.001 par value per share 19536 0 D Warrant (right to purchase Common Stock) 3.4375 2015-04-30 Common Stock, $0.001 par value per share 7900 0 D Stock Option (right to buy) 5.62 2025-03-01 Common Stock, $0.001 par value per share 50000 50000 D The reporting person beneficially owns these securities through Wade Capital Corporation Money Purchase Plan (an entity for which he has voting and investment control). The options vested 100% on January 10, 2014. On January 8, 2014, the reporting person acquired in a private placement (i) 4,500 shares of the Company's Series C-3 Non-Voting Convertible Preferred Stock, each share is convertible into 10 shares of Common Stock, $0.001 par value per share at a conversion price of $1.00 per share; and (ii) a five-year warrant to purchase common stock at an exercise price of $1.25 per share. The Series C-3 Preferred Stock and the warrants were purchased together at a purchase price of $10.00 per share for each share of Series C-3 Preferred Stock. On January 8, 2014, the reporting person, through his ownership in Wade Capital Corporation Money Purchase Plan (an entity for which he has voting and investment control), acquired in a private placement (i) 3,000 shares of the Company's Series C-3 Non-Voting Convertible Preferred Stock, each share is convertible into 10 shares of Common Stock, $0.001 par value per share at a conversion price of $1.00 per share; and (ii) a five-year warrant to purchase common stock at an exercise price of $1.25 per share. The warrant exercise price was decreased from $1.25 per share to $0.90 per share effective September 15, 2014. The Series C-3 Preferred Stock and the warrants were purchased together at a purchase price of $10.00 per share for each share of Series C-3 Preferred Stock. These options vest quarterly over two years beginning June 13, 2013. These options vested as follows: (a) fifty percent (50%) on the date of issuance of the CE Mark certification for Neutrolin in Europe, which occuured on July 5, 2013, and (b) fifty percent (50%) on December 31, 2013. The options vest in full on the first anniversary of the date of grant. The options vest ratably, one-third of which will vest on each of the grant date, the first anniversary and the second anniversary thereof. The warrants were issued as part of the Company's initial public offering in March 2010 and were exercisable beginning six months after the effective date of hte Company's registration statement related thereto. The expiration date was originally 3/24/2015 and was extended to 4/30/2015. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices $6.15 to $6.17, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices $6.15 to $7.10, inclusive. /s/Alexander M. Donaldson by Power of Attorney 2015-06-01